{"id":22302,"date":"2019-09-19T07:39:16","date_gmt":"2019-09-19T07:39:16","guid":{"rendered":"https:\/\/wames.org.uk\/cms-english\/?p=22302"},"modified":"2019-09-19T07:39:50","modified_gmt":"2019-09-19T07:39:50","slug":"towards-a-biomarker-rethinking-me-cfs-diagnostic-reference-intervals-via-machine-learning-the-utility-of-activin-b-for-defining-symptom-severity","status":"publish","type":"post","link":"https:\/\/wames.org.uk\/cms-english\/towards-a-biomarker-rethinking-me-cfs-diagnostic-reference-intervals-via-machine-learning-the-utility-of-activin-b-for-defining-symptom-severity\/","title":{"rendered":"Towards a biomarker: Rethinking ME\/CFS diagnostic reference intervals via machine learning, & the utility of activin B for defining symptom severity"},"content":{"rendered":"

Rethinking ME\/CFS diagnostic reference intervals via machine learning, and the utility of activin B for defining symptom severity<\/a>, by Brett A. Lidbury, Badia Kita, Alice M Richardson, Donald P Lewis, Edwina Privitera, Susan Hayward, David de Kretser and Mark Hedger in<\/span> Diagnostics<\/em> 2019, 9(3), 79; https:\/\/doi.org\/10.3390\/diagnostics9030079<\/h3>\n

 <\/p>\n

Research abstract:<\/strong><\/h3>\n

\"Test<\/a><\/p>\n

Biomarker discovery applied to myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS), a disabling disease of inconclusive aetiology, has identified several cytokines to potentially fulfil a role as a quantitative blood\/serum marker for laboratory diagnosis, with activin B a recent addition.<\/p>\n

We explored further the potential of serum activin B as a ME\/CFS biomarker, alone and in combination with a range of routine test results obtained from pathology laboratories.<\/p>\n

Previous pilot study results showed that activin B was significantly elevated for the ME\/CFS participants compared to healthy (control) participants. All the participants were recruited via CFS Discovery and assessed via the Canadian\/International Consensus Criteria.<\/p>\n

A significant difference for serum activin B was also detected for ME\/CFS and control cohorts recruited for this study, but median levels were significantly lower for the ME\/CFS cohort. Random Forest (RF) modelling identified five routine pathology blood test markers that collectively predicted ME\/CFS at \u226562% when compared via weighted standing time (WST) severity classes.<\/p>\n

A closer analysis revealed that the inclusion of activin B to the panel of pathology markers improved the prediction of mild to moderate ME\/CFS cases. Applying correct WST class prediction from RFA modelling, new reference intervals were calculated for activin B and associated pathology markers, where 24-h urinary creatinine clearance, serum urea and serum activin B showed the best potential as diagnostic markers.<\/p>\n

While the serum activin B results remained statistically significant for the new participant cohorts, activin B was found to also have utility in enhancing the prediction of symptom severity, as represented by WST class.<\/p>\n

Australian researchers explored a potentially effective method of identifying ME\/CFS by using a combination of cytokines. By grouping activin B with 24-hour urinary creatinine clearance and serum urea together for analysis, the results show good potential for use in diagnosing ME\/CFS. Activin B is a complex protein found to have biological effects in numerous bodily functions.<\/p>\n

A previous\u00a0pilot study showed a significant increase of activin B in ME\/CFS patients as compared to healthy controls. The researchers found that including\u00a0activin B in the panel of pathology markers improved prediction rates for\u00a0mild and moderate cases of ME\/CFS.\u00a0Additionally, activin B was also found to help with\u00a0the prediction of symptom\u00a0severity as represented by weighted standing time tests.<\/p>\n

**This paper is from the Emerge Australia sponsored issue of\u00a0Diagnostics<\/p>\n","protected":false},"excerpt":{"rendered":"

Rethinking ME\/CFS diagnostic reference intervals via machine learning, and the utility of activin B for defining symptom severity, by Brett A. Lidbury, Badia Kita, Alice M Richardson, Donald P Lewis, Edwina Privitera, Susan Hayward, David de Kretser and Mark Hedger … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[4351,4352,4170,113,5319,93,3806,5321,813,5318,3270,5322,5320],"class_list":["post-22302","post","type-post","status-publish","format-standard","hentry","category-news","tag-alice-m-richardson","tag-badia-kita","tag-biomarker","tag-cytokines","tag-david-de-kretser","tag-diagnosis","tag-donald-p-lewis","tag-edwina-privitera","tag-illness-severity","tag-mark-hedger","tag-prof-brett-lidbury","tag-serum-activin-b","tag-susan-hayward"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p5qkYK-5NI","_links":{"self":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/22302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/comments?post=22302"}],"version-history":[{"count":5,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/22302\/revisions"}],"predecessor-version":[{"id":22504,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/posts\/22302\/revisions\/22504"}],"wp:attachment":[{"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/media?parent=22302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/categories?post=22302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wames.org.uk\/cms-english\/wp-json\/wp\/v2\/tags?post=22302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}